Patient outcomes improve when a molecular signature test guides treatment decision-making in rheumatoid arthritis.
Jeffrey R CurtisVibeke StrandSteven GolombekLixia ZhangAngus WongMark C ZielinskiViatcheslav R AkmaevAlif SalehSam AsgarianJohanna B WithersPublished in: Expert review of molecular diagnostics (2022)
MSRC clinical validity supports high clinical utility: guided treatment selection resulted in significantly superior outcomes relative to standard care; nearly three times more patients reached CDAI remission.
Keyphrases
- rheumatoid arthritis
- end stage renal disease
- healthcare
- chronic kidney disease
- ejection fraction
- newly diagnosed
- disease activity
- prognostic factors
- metabolic syndrome
- adipose tissue
- ankylosing spondylitis
- weight loss
- insulin resistance
- single molecule
- replacement therapy
- affordable care act
- smoking cessation
- patient reported